中德证券有限责任公司 关于北京热景生物技术股份有限公司募集资金投资项目结项 并将节余募集资金永久补充流动资金的核查意见 中德证券有限责任公司（以下简称"中德证券"或"保荐机构"）作为北京 热景生物技术股份有限公司（以下简称"热景生物"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《上市公司监管指引第 2 号——上市公司 募集资金管理和使用的监管要求》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关法律法 规的规定，对热景生物募集资金投资项目结项并将节余募集资金永久补充流动资 金事项进行了认真、审慎的核查，核查情况如下： 根据公司披露的《北京热景生物技术股份有限公司首次公开发行股票并在科 创板上市招股说明书》《北京热景生物技术股份有限公司关于使用部分超募资金 永久补充流动资金的公告》（公告编号：2020-010）《北京热景生物技术股份有限 公司关于使用部分超募资金购买土地使用权用于扩大募集资金投资项目实施场地 的公告》（公告编号：2020-025）《北京热景生物技术股份有限公司关于使用剩余 1 超募资金投资建设"全场景免疫诊断仪器、试剂 ...

证券代码：688068 证券简称：热景生物 公告编号：2023-047 北京热景生物技术股份有限公司关于 职工代表监事因参与补选董事辞去原监事职务暨补 选职工代表监事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"热景生物"或"公司"）监事 会于近日收到职工代表监事李艳召先生的书面辞职报告。因职务调整，李艳召先 生申请辞去原公司第三届监事会职工代表监事职务并参与补选公司第三届董事 会董事职务。 截至本公告披露日，李艳召先生通过青岛同程热景企业管理咨询合伙企业 （有限合伙）间接持有公司股份 103,649 股，约占公司总股本的 0.1123%。李艳 召先生承诺将继续遵守《上海证券交易所科创板股票上市规则》《上海证券交易 所上市公司股东及董事、监事、高级管理人员减持股份实施细则》等相关法律法 规对监事股份转让的规定及公司首次公开发行股票时所作的相关承诺。 根据《中华人民共和国公司法》《公司章程》等规定，李艳召先生辞去职工 代表监事职务将导致公司监事会人数低于法定最低人数，为保障监 ...

证券代码：688068 证券简称：热景生物 公告编号：2023-048 北京热景生物技术股份有限公司 关于补选第三届董事会非独立董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"热景生物"或"公司"）于 2023 年 9 月 13 日召开第三届董事会第十二次会议，会议审议通过了《关于补选第三 届董事会非独立董事的议案》，现将补选情况公告如下： 一、董事辞职情况 董事会于 2023 年 6 月 19 日收到董事、核心技术人员孙志伟先生的书面辞职 报告。孙志伟先生因个人原因申请辞去公司董事、公司董事会战略委员会、公司 董事会提名委员会委员职务，其辞职报告自送达公司董事会之日起生效，孙志伟 先生辞去公司上述职务后，将专职于公司重要参股公司北京舜景生物医药技术有 限公司的研发工作并担任总经理。 根据《中华人民共和国公司法》《公司章程》等有关规定，孙志伟先生的辞 职未导致公司董事会成员低于法定人数，不会影响公司董事会的正常运行。公司 将按照法定程序尽快补选董事。 二、补选董事情况 特 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[1]. - The company's operating revenue for the first half of 2023 was ¥307,007,061.27, a decrease of 84.99% compared to the same period last year[22]. - Net profit attributable to shareholders for the same period was ¥84,768,666.87, down 89.60% year-on-year[22]. - The basic earnings per share decreased by 89.27% to ¥0.95, while the diluted earnings per share also fell by the same percentage[24]. - The total revenue for the first half of 2023 was CNY 47.8 billion, with a net profit of CNY 6.81 billion, representing a decrease of 2.14% compared to the previous year[69]. - The company reported a revenue of CNY 30,700.71 million for the reporting period, a decrease of 84.99% year-on-year[123]. - The net profit attributable to the parent company was CNY 8,476.87 million, down 89.60% compared to the previous year[123]. Research and Development - The company is investing in R&D, with a budget allocation of RMB 50 million for the development of new technologies in the next fiscal year[1]. - Research and development expenses accounted for 22.19% of operating revenue, an increase of 18.19 percentage points year-on-year[24]. - The number of R&D personnel increased to 319, reflecting an 18.59% growth compared to the same period last year[25]. - The company has developed a digital AI diagnostic model, C-GALAD II, for liver cancer risk warning, enhancing its product offerings in liver disease diagnostics[33]. - The company has established a future technology research institute to explore cutting-edge technologies in the biopharmaceutical field, including antibody and nucleic acid drugs[34]. - The company has developed 12 diagnostic indicators for liver diseases, including three for liver cancer, and has obtained 19 registration numbers for testing reagents[108]. - The company has made significant progress in antibody drug development, with 10 products in the pipeline, including 5 that have completed molecular discovery[107]. Market Expansion and Strategy - Market expansion efforts are underway, targeting Southeast Asia, with plans to enter three new countries by Q4 2023[1]. - A new marketing strategy has been implemented, focusing on digital channels, which is expected to increase customer engagement by 30%[1]. - The company aims to strengthen its core in vitro diagnostics business while actively expanding into new fields and strategic layouts[24]. - The company is actively expanding its product offerings in the in vitro diagnostic field, including the development of liquid biopsy technologies for early cancer screening[73]. - The company has established collaborations with several medical institutions for early cancer diagnosis projects, indicating a strong focus on research partnerships[55]. Product Development and Innovation - New product launches include a state-of-the-art diagnostic kit that is expected to contribute an additional RMB 100 million in revenue by the end of the year[1]. - The company has developed the first NMPA-approved HBV-RNA detection kit in China, marking a significant milestone in the domestic market[50]. - The company has launched a series of fully automated chemiluminescence immunoassay products, recommended for use in tertiary hospitals for chest pain centers[51]. - The company has developed a liver cancer early diagnosis triad test (AFP, AFP-L3%, DCP) that significantly improves early detection rates of liver cancer[74]. - The GlyExo-Capture technology allows for rapid separation of exosomes in just 11 minutes, significantly improving the efficiency of liquid biopsy applications for early cancer diagnosis[54]. - The company has developed a unique "GlyExo-Capture" technology for exosome-based liver cancer early diagnosis, which has received two national invention patents and is expected to be the first approved exosome liver cancer diagnostic product in China[87]. Financial Health and Investments - The company's cash flow from operating activities showed a net outflow of ¥199,519,286.00, a decline of 143.94% compared to the previous year[22]. - The total assets decreased by 5.08% to ¥3,701,105,080.45 compared to the end of the previous year[22]. - The company has received multiple awards for its innovative diagnostic technologies, including the National Technology Invention Award and various provincial and national recognitions for its products[45][46]. - The company has obtained 701 medical device registration/filing certificates, with 17 new registrations during the reporting period[62]. - The company has received 41 registration certificates for up-conversion luminescence technology, with 35 reagents and 6 instruments registered, and has 5 products under development[57]. Corporate Governance and Compliance - The board of directors has confirmed that there are no non-operational fund usages by controlling shareholders or related parties[1]. - The company has committed to avoiding competition with its controlling shareholders and related parties, ensuring no similar business activities are conducted[156]. - The company has not reported any significant related party transactions, maintaining transparency in its operations[159]. - The company has no reported environmental penalties during the reporting period, indicating compliance with environmental regulations[150]. - The company has not disclosed any major violations or penalties against its directors, supervisors, or senior management during the reporting period[171]. Legal and Regulatory Matters - There are significant litigation and arbitration matters during the reporting period, with ongoing cases involving a total claim amount of RMB 26,943,040.26[167]. - The company is currently in the process of reviewing its fundraising project details, with no significant changes reported[175]. - The company has initiated multiple lawsuits against Jilin Rejing, including a request for changes in company registration and shareholder information rights[170]. - A court ruling on January 9, 2023, ordered the return of company credentials to Fu Yumin, with the case still under appeal[169].

证券代码：688068 证券简称：热景生物 公告编号：2023-045 北京热景生物技术股份有限公司 第三届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 北京热景生物技术股份有限公司（以下简称"公司"）第三届监事会第十一 次会议于 2023 年 8 月 28 日以现场和通讯相结合的方式在（公司总部会议室/线 上）召开。本次会议的通知于 2023 年 8 月 18 日以邮件、微信的方式送达全体监 事。本次会议应出席监事 3 人，实际出席监事 3 人，会议由监事会主席李靖召集 并主持。会议的召集、召开符合《中华人民共和国公司法》、《上海证券交易所科 创板股票上市规则》等相关法律、行政法规、规范性文件及《北京热景生物技术 股份有限公司章程》的有关规定。 二、监事会会议审议情况 经审议，公司监事会全体监事认为公司《2023 年半年度报告》的编制和审 议程序符合相关法律法规、《公司章程》及公司内部管理制度的各项规定；公司 《2023 年半年度报告》的内容与格式符合中国证券监督管 ...

证券代码：688068 证券简称：热景生物 公告编号：2023-046 北京热景生物技术股份有限公司2023年半年度 募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、募集资金基本情况 （一）实际募集资金金额及资金到账时间 依据中国证券监督管理委员会出具《关于同意北京热景生物技术股份有限公 司首次公开发行股票注册的批复》（证监许可〔2019〕1615 号），同意北京热景生 物技术股份有限公司（以下简称"公司"、"本公司"、"热景生物"）向社会公开 发行人民币普通股 1,555.00 万股，发行价格为 29.46 元/股，共计募集资金人民币 45,810.30 万元，扣除发行费用（包括保荐费、承销费、审计及验资费、律师费、 信息披露费、发行手续费等）合计人民币 5,903.21 万元（不含增值税）后，实际 募集资金净额为人民币 39,907.09 万元。上述募集资金已于 2019 年 9 月 24 日全 部到位，并由容诚会计师事务所（特殊普通合伙）于 2019 年 9 月 25 日对本 ...

北京热景生物技术股份有限公司独立董事关于第三届董事会第十一次会议相关事项的独立意见 (此页无正文,仅为《北京热景生物技术股份有限公司独立董事关于第三届董事 会第十一次会议相关事项的独立意见》之签字页） 北京热景生物技术股份有限公司独立董事 关于第三届董事会第十一次会议相关事项的独立意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易 所科创板股票上市规则》、《关于在上市公司建立独立董事制度的指导意见》、《北 京热景生物技术股份有限公司章程》(以下简称"《公司章程》")等有关规定,北 京热景生物技术股份有限公司(以下简称"公司")全体独立董事喻长远、宋云 锋、徐小舸本着忠实勤勉、认真负责的态度对公司于 2023年8月28日召开的第 三届董事会第十一次会议的相关议案进行了认真审议,发表如下意见: 一、《关于审议<2023 年半年度募集资金存放与实际使用情况专项报告>的议 案》 经审查,作为公司独立董事我们认为公司 2023年半年度募集资金存放与实 际使用情况符合《上海证券交易所科创板股票上市规则》《上海证券交易所科创 板上市公司自律监管规则适用指引第1号 -- 规范运作》、《上市公司监管指 ...

Financial Performance - The net profit attributable to shareholders for 2022 was ¥944,736,633.48, with undistributed profits of ¥2,728,180,599.39[6] - The company plans to not distribute cash dividends, issue bonus shares, or convert reserves into share capital for the 2022 profit distribution[6] - The company's operating revenue for 2022 was ¥3,556,551,569.15, a decrease of 33.76% compared to ¥5,369,203,761.63 in 2021[21] - The net profit attributable to shareholders for 2022 was ¥944,736,633.48, down 56.78% from ¥2,185,763,390.61 in 2021[21] - The net profit excluding non-recurring gains and losses was ¥942,414,646.53, a decrease of 56.65% compared to ¥2,174,116,111.10 in 2021[21] - Cash flow from operating activities for 2022 was ¥978,753,167.93, down 62.99% from ¥2,644,481,598.61 in 2021[21] - Basic earnings per share decreased by 56.51% to CNY 10.33 in 2022 from CNY 23.75 in 2021[22] - The weighted average return on equity dropped by 92.02 percentage points to 30.41% in 2022 from 122.43% in 2021[22] - The net profit attributable to shareholders in Q4 2022 was a loss of CNY 156.77 million, marking a significant decline compared to previous quarters[24] - The total amount of non-recurring gains and losses for 2022 was CNY 2.32 million, a decrease from CNY 11.65 million in 2021[27] Risk Factors - There are no significant adverse risk factors impacting the company during the reporting period[4] - The company has outlined potential risks related to forward-looking statements in the report[7] - The company faces risks related to new product development, including potential delays and failures due to technical challenges and market positioning[136] - The company emphasizes the importance of retaining high-quality technical personnel, as their loss could delay ongoing projects and impact future product development[137] - The company is exposed to risks from potential changes in government pricing policies and procurement regulations[141] - The ongoing geopolitical tensions, such as the US-China trade friction and the Russia-Ukraine conflict, may impact the company's foreign trade operations[145] Research and Development - The company invested a total of 191.14 million yuan in R&D in 2022, a significant increase of 59.22 million yuan, representing a year-on-year growth of 44.89%[38] - Research and development expenses accounted for 5.37% of operating revenue, an increase of 2.91 percentage points compared to 2.46% in 2021[22] - The company has established advanced technology platforms, including phage display technology and glycan capture technology, enhancing its core competitiveness in the field of in vitro diagnostics[87] - The company is actively exploring new technologies and fields, including liquid biopsy for early cancer screening and collaborations with academic institutions for research and development[100] - The company has expanded its R&D team by 13.50% to 269 members, with an average salary increase of 11.50% to CNY 295,800[98] Market Expansion and Strategy - The company is focused on expanding its market presence and developing new technologies in the field of immunodiagnostics and molecular diagnostics[20] - Future outlook includes continued investment in research and development to enhance product offerings and market competitiveness[20] - The company aims to improve operational efficiency and reduce costs in response to declining revenues[20] - The company aims to enhance its market share in clinical medical testing, early liver cancer detection, and public safety testing in 2023[185] - The company will focus on developing antibody drugs, live bacteria drugs, and nucleic acid drugs as part of its biopharmaceutical innovation strategy[186] Product Development and Innovation - The company is actively developing liquid biopsy technologies for early cancer screening, including glycan exosome and DNA methylation techniques, with the GlyExo-CaptureTM technology receiving two national invention patents[32][33] - The company has launched a comprehensive liver health management strategy, including a liver cancer risk warning model "C-GALAD II" and various diagnostic products, achieving CNY 84.02 million in revenue from hepatitis and liver cancer testing reagents[35][36] - The company has developed the first NMPA-approved product for early diagnosis of liver cancer using "sugar capture technology" and the first fluorescent quantitative detection kit for HBV RNA in China[74] - The company has developed a unique "GlyExo-Capture" technology for exosome-based liver cancer early diagnosis, which has received two national invention patents[122] Financial Health and Assets - Total assets at the end of 2022 were ¥3,899,271,839.82, an increase of 6.98% from ¥3,644,844,550.64 at the end of 2021[21] - Net assets attributable to shareholders increased by 17.29% to ¥3,335,223,635.33 at the end of 2022 from ¥2,843,524,711.02 at the end of 2021[21] - Cash and cash equivalents at the end of the period amounted to ¥523,493,118.90, representing 13.43% of total assets, a decrease of 54.91% compared to the previous period[168] - Total liabilities increased by 48.42% to ¥263,443,202.57, primarily due to an increase in accounts payable for engineering equipment[171] Corporate Governance and Compliance - The company has improved its internal governance and control systems to ensure timely, accurate, and complete information disclosure to investors[49] - The board of directors and supervisory board members confirmed the authenticity, accuracy, and completeness of the annual report[4] - The company maintained a mixed sales model, with distribution accounting for the majority of sales, while direct sales showed a significant increase in gross margin compared to distribution[155] - The company aims to maintain a governance structure that complies with relevant laws and regulations, ensuring effective operation and protection of investor interests[190] Awards and Recognition - As of the end of the reporting period, the company has received over 50 honors, including "Beijing Enterprise Technology Center" and "Beijing Intellectual Property Operation Pilot Unit"[52] - The company was recognized as a "Little Giant" enterprise in Beijing for 2021 and received multiple awards for its contributions to technology and innovation in 2022[53] - The company has received multiple awards for its innovative technologies, including the National Technology Invention Award and various provincial and national recognitions for its automatic immunoassay analyzers[72][73]

证券代码：688068 证券简称：热景生物 公告编号：2023-029 北京热景生物技术股份有限公司关于 召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 北京热景生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年度报告和 2023 年度第一季度报告，为便于广大投资者更全面 深入地了解公司 2022 年度和 2023 年一季度经营成果、财务状况，公司计划于 2023 年 06 月 02 日下午 13:00-14:00 举行 2022 年度暨 2023 年第一季度业绩说 明会，就投资者关心的问题进行交流。 一、 说明会类型 会议召开时间：2023 年 06 月 02 日(星期五) 下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投 ...

Financial Performance - The net profit attributable to shareholders for 2022 was ¥944,736,633.48, with undistributed profits of ¥2,728,180,599.39 on the parent company’s balance sheet [6]. - The company plans to not distribute cash dividends, issue bonus shares, or convert reserves into share capital for the 2022 profit distribution, opting to carry forward undistributed profits to the next year [6]. - The company's operating revenue for 2022 was approximately ¥3.56 billion, a decrease of 33.76% compared to ¥5.37 billion in 2021 [21]. - The net profit attributable to shareholders for 2022 was approximately ¥944.74 million, down 56.78% from ¥2.19 billion in 2021 [21]. - Cash flow from operating activities for 2022 was approximately ¥978.75 million, a decline of 62.99% from ¥2.64 billion in 2021 [21]. - Basic earnings per share decreased by 56.51% to CNY 10.33 in 2022 from CNY 23.75 in 2021 [22]. - The weighted average return on equity dropped to 30.41% in 2022, down 92.02 percentage points from 122.43% in 2021 [22]. - The gross profit margin for the year was 53.71%, down 5.83 percentage points from the previous year, attributed to declining sales prices of COVID-19 antigen test products [151]. - The company achieved operating revenue of 3,556.55 million RMB, a year-on-year decrease of 33.76% [146]. - The net profit attributable to the parent company was 944.74 million RMB, down 56.78% year-on-year [146]. Risk Factors - There are no significant risk factors that could adversely affect the company during the reporting period [4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties [8]. - The company has faced risks related to new product development, including potential delays and failures due to technical route deviations and market positioning issues [136]. - The company is at risk of losing core technical personnel, which could delay ongoing projects and negatively impact future product development [137]. - The company faces risks related to new product registration failures due to regulatory changes and quality management system compliance [138]. - There is a risk of intensified competition in the in vitro diagnostics industry, with potential impacts on market share and profitability [139]. - The pricing model for diagnostic reagents is influenced by government policies, which may lead to price reductions if not managed properly [140]. - The company must continuously upgrade its technology and products to meet market demands, or face risks related to technological obsolescence [143]. - The company is subject to strict regulatory management in the in vitro diagnostics sector, which requires timely adjustments to operational strategies [144]. - The rapid growth of the company necessitates improvements in management and internal controls to maintain competitive advantage [145]. Corporate Governance - The company received a standard unqualified audit report from Rongcheng Accounting Firm [5]. - The board of directors and supervisory board members confirmed the authenticity, accuracy, and completeness of the annual report [4]. - There are no special arrangements for corporate governance applicable to the company [9]. - The company has continuously improved its internal governance and control systems to ensure timely and accurate information disclosure to investors [50]. - The company adheres to strict corporate governance practices, ensuring compliance with relevant laws and regulations [189]. Research and Development - The company is focused on developing new technologies such as Anti-Stokes luminescence and chemiluminescence immunoassay methods [13]. - The company invested a total of 191.14 million yuan in R&D in 2022, a significant increase of 59.22 million yuan, representing a year-on-year growth of 44.89% [38]. - Research and development expenses accounted for 5.37% of operating revenue, an increase of 2.91 percentage points compared to 2.46% in 2021 [22]. - The company has developed a proprietary glycan exosome detection technology, which has received two national invention patents and is aimed at early cancer diagnosis and screening [32]. - The company is advancing its DNA methylation technology for cancer screening, focusing on liver cancer and other gastrointestinal tumors, with a new product "Xiao Wei An" developed for early detection [33]. - The company has registered 19 testing reagent numbers for liver disease diagnosis, including three for liver cancer, and has launched a digital AI diagnostic model for liver cancer risk [35]. - The company has developed a liver cancer early diagnosis reagent kit based on its proprietary technology, which is now commercially available [102]. - The company has established a Future Technology Research Institute to explore cutting-edge technologies in biopharmaceuticals, including antibody drugs, live bacteria drugs, and nucleic acid drugs [185]. - The company has a strong R&D team and has maintained high R&D investment to ensure continuous innovation and technological accumulation [87]. Market Expansion and Strategy - The company aims to enhance its product offerings and market strategies in the upcoming fiscal year [21]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth [29]. - The company is expanding its foreign trade business, but risks from US-China trade tensions and the Russia-Ukraine conflict could impact operations [141]. - The company plans to enhance its market share in clinical medical testing, early liver cancer detection, and public safety testing, with a focus on product innovation and differentiation strategies [184]. - The company is actively exploring innovative biopharmaceuticals, with 8 therapeutic monoclonal antibody projects in development, 4 of which have completed molecular discovery [112]. - The company is strategically expanding into therapeutic antibody drug development and nucleic acid drug research, indicating a diversification of its product offerings [78]. - The company is focused on talent development, implementing training programs and recruitment strategies to attract high-quality talent for various operational areas [187]. - The company is committed to optimizing its production layout and improving operational efficiency through the new production facilities [187]. Product Development and Innovation - The company has developed a unique alpha-fetoprotein heterogeneity test reagent for early liver cancer diagnosis, which is the first of its kind approved by NMPA in China [74]. - The company has developed the "GlyExo-Capture" technology for capturing tumor-specific glycan exosomes, which allows for complete and biologically active exosome separation in just 11 minutes, significantly enhancing early cancer screening capabilities [89]. - The company has launched a home-use COVID-19 antigen self-test kit, which received Emergency Use Authorization (EUA) from the FDA in November 2022, making it one of the few products with multiple international certifications [40]. - The company has developed a portable rapid nucleic acid testing system, integrating multiple advanced technologies for quick detection of respiratory pathogens [41]. - The company has developed a unique immunodiagnostic instrument platform that covers a wide range of applications, making it one of the few suppliers with a comprehensive product line in the industry [124]. Awards and Recognition - As of the end of the reporting period, the company has received over 50 honors, including "Beijing Enterprise Technology Center" and "Beijing Intellectual Property Operation Pilot Unit" [52]. - The company was recognized as a "Little Giant" enterprise in Beijing for 2021 and received multiple awards for its contributions to technology and innovation throughout 2022 [53]. - The company has received multiple awards for its innovative diagnostic technologies, including the National Technology Invention Award and various provincial and national recognitions for its automatic immunoassay analyzers [72][73]. Social Responsibility - The company has actively participated in social responsibility initiatives, donating over RMB 1 million to support pandemic control efforts in various regions [55].